Key Points
- CFO Robert Goeltz II sold 6,552 shares on Dec. 31 at an average of $23.38 for $153,185.76, trimming his stake by 8.8% to 67,924 shares (about $1.59M).
- Arcus reported quarterly EPS of ($1.27), beating estimates, and revenue of $26.0M (also above estimates) but revenue was down 45.8% year‑over‑year and the company remains unprofitable with negative margins.
- The stock has a market cap of $2.51B and a 1‑year range of $6.50–$26.40; analysts have a consensus rating of "Moderate Buy" with a average price target of $28.89, and institutional investors own about 92.9% of the shares.
Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) CFO Robert Goeltz II sold 6,552 shares of the company's stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $23.38, for a total transaction of $153,185.76. Following the completion of the transaction, the chief financial officer directly owned 67,924 shares of the company's stock, valued at approximately $1,588,063.12. The trade was a 8.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Arcus Biosciences Stock Down 2.6%
Shares of RCUS stock opened at $23.22 on Friday. The firm's fifty day moving average price is $22.39 and its two-hundred day moving average price is $15.08. Arcus Biosciences, Inc. has a 1 year low of $6.50 and a 1 year high of $26.40. The company has a current ratio of 3.65, a quick ratio of 3.65 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $2.51 billion, a P/E ratio of -6.75 and a beta of 0.75.
Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.33) by $0.06. The firm had revenue of $26.00 million for the quarter, compared to analyst estimates of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The business's revenue for the quarter was down 45.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.00) earnings per share. On average, equities analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.
Institutional Trading of Arcus Biosciences
Several hedge funds have recently made changes to their positions in RCUS. Amalgamated Bank grew its holdings in Arcus Biosciences by 3.9% during the 3rd quarter. Amalgamated Bank now owns 19,533 shares of the company's stock valued at $266,000 after buying an additional 736 shares in the last quarter. Creative Planning lifted its stake in Arcus Biosciences by 2.7% during the third quarter. Creative Planning now owns 29,629 shares of the company's stock worth $403,000 after purchasing an additional 771 shares during the last quarter. GAMMA Investing LLC lifted its position in Arcus Biosciences by 59.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company's stock worth $37,000 after buying an additional 1,021 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Arcus Biosciences by 8.0% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company's stock valued at $142,000 after purchasing an additional 1,294 shares in the last quarter. Finally, Parallel Advisors LLC lifted its stake in Arcus Biosciences by 1.6% in the second quarter. Parallel Advisors LLC now owns 88,007 shares of the company's stock worth $716,000 after purchasing an additional 1,422 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on the stock. Citigroup reissued a "buy" rating on shares of Arcus Biosciences in a report on Friday, December 12th. Wells Fargo & Company upped their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the company an "overweight" rating in a research note on Monday, October 20th. The Goldman Sachs Group raised their target price on Arcus Biosciences from $14.00 to $16.00 and gave the stock a "neutral" rating in a research report on Thursday, October 30th. Wall Street Zen upgraded shares of Arcus Biosciences from a "sell" rating to a "hold" rating in a research report on Sunday, December 14th. Finally, UBS Group reiterated a "buy" rating on shares of Arcus Biosciences in a report on Monday, December 15th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $28.89.
View Our Latest Analysis on RCUS
Arcus Biosciences Company Profile
(
Get Free Report)
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company's research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.
The company's lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
